Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration to manufacture and market Olanzapine tablets.
Olanzapine tablets are the generic equivalent of Eli Lilly & Company’s Zyprexa tablets. They are indicated for the treatment of serious psychotic disorders such as schizophrenia and falls under the neurological therapeutic category.
Annual sale of olanzapine was approximately $3.2 billion and it is ready for launch, the Hyderabad-based company said in a release on Wednesday.